Business Week Recognizes Syncor as a Top Performer Among S&P SmallCap 600 Companies.Business Editors & Health/Medical Writers WOODLAND HILLS, Calif.--(BUSINESS WIRE)--April 6, 2001 Company Ranked Third Out of 600 Companies, Based on One- and Three-Year Stock Performance Syncor International Corporation (Nasdaq:SCOR SCOR Scientific Committee on Oceanic Research SCOR Supply Chain Operations Reference model SCOR Small Corporate Offering Registration SCOR Specialized Center of Research (White Plains, NY) SCOR Second Cousin Once Removed ) today announced that it has been recognized by Business Week as a top performer among S&P SmallCap 600 Index companies. Syncor was ranked third out of the 600 companies comprising this index. To determine its rankings, Business Week ranked the stocks in the index by one- and three-year stock market performance as of February 16, 2001. Business Week then added these two rankings to develop the overall ranking. Robert Funari, president and chief executive officer of Syncor said, "Syncor's strong stock market performance is due not only to our success in delivering in excess of forty percent compounded growth in net income over the last three years, but is also reflective of the market's assessment of our prospects for future growth. We are very proud to have received this recognition, and look forward to working to deliver continued strong results." About Syncor Syncor International Corporation is a leading provider of high technology health care services concentrating on nuclear pharmacy Nuclear Pharmacy involves the preparation of radioactive materials that will be used to diagnose and treat specific diseases. It was the first pharmacy specialty established in 1978 by the Board of Pharmaceutical Specialties. services, medical imaging, niche manufacturing and radiotherapy. In the nuclear pharmacy services business, Syncor compounds and dispenses radiopharmaceuticals for diagnostic and therapeutic use by nuclear medicine departments in hospitals and outpatient clinics. Syncor distributes these time-critical pharmaceuticals through an integrated network A network that supports both data and voice and/or different networking protocols. See converged network and new public network. of more than 127 domestic and 19 international nuclear pharmacies. Medical imaging services are provided through an integrated network of 58 domestic and 13 international owned or operated facilities (including two catheterization catheterization Threading of a flexible tube (catheter) through a channel in the body to inject drugs or a contrast medium, measure and record flow and pressures, inspect structures, take samples, diagnose disorders, or clear blockages. laboratories overseas). Domestic medical imaging operations are conducted by Syncor's wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , Comprehensive Medical Imaging Inc. and international operations Internal Operations (I.O., IO or I/O) is a fictional American Intelligence Agency in Wildstorm comics. It was originally called International Operations. I.O. first appeared in WildC.A.T.S. volume 1 #1 (August, 1992) and was created by Brandon Choi and Jim Lee. are conducted by Syncor Overseas Ltd. Syncor also owns or operates two domestic and two international production facilities for positron emission tomography positron emission tomography: see PET scan. positron emission tomography (PET) Imaging technique used in diagnosis and biomedical research. (PET) radiopharmaceuticals, and is a party to a series of agreements to make PET technology more accessible to healthcare providers and patients nationwide. This network also provides information management services and currently services more than 7,000 customers. Syncor also produces and markets Iodine-125 brachytherapy seeds used to treat prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion